- Bay 59-3074
-
- $31.00
-
2026-08-08
- CAS:406205-74-1
- Purity: 98.00%
- Supply Ability: 10g
|
| | Bay 59-3074 Basic information |
| Product Name: | Bay 59-3074 | | Synonyms: | 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl4,4,4-trifluoro-1-butanesulfonicacidester;CS-2278;BAY-59-3074; BAY 59-3074; BAY59-3074;BAY 59-3074;BAY-59-3074;1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl ester;inhibit,Cannabinoid Receptor,Bay 59-3074,Inhibitor,Bay 593074,Bay 59 3074;Bay 59-3074, 10 mM in DMSO;Bay 59-3074 ，S0412 | | CAS: | 406205-74-1 | | MF: | C18H13F6NO4S | | MW: | 453.36 | | EINECS: | | | Product Categories: | Pharmaceutical intermediate | | Mol File: | 406205-74-1.mol |  |
| | Bay 59-3074 Chemical Properties |
| Boiling point | 490.6±45.0 °C(Predicted) | | density | 1.49±0.1 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMSO:56.78(Max Conc. mg/mL);135.05(Max Conc. mM)
Ethanol:68.17(Max Conc. mg/mL);162.14(Max Conc. mM) | | form | A crystalline solid | | color | White to off-white |
| | Bay 59-3074 Usage And Synthesis |
| Uses | Bay 59-3074, is a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects. | | Definition | ChEBI: 4,4,4-trifluoro-1-butanesulfonic acid is an aromatic ether. | | Biological Activity | Novel CB 1 /CB 2 receptor partial agonist (K i values are 48.3 and 45.5 nM at human CB 1 and CB 2 receptors respectively). Orally active CB 1 agonist in vivo . Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain. | | in vivo | BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain. | Animal Model: | Male Wistar rats (160-250 g)[1] | | Dosage: | 0.3 mg/kg, 1 mg/kg, and 3 mg/kg | | Administration: | Oral administration; daily; for 2 weeks. | | Result: | Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.
|
| | IC 50 | CB1: 48.3 nM (Ki); CB2: 45.5 nM (Ki) |
| | Bay 59-3074 Preparation Products And Raw materials |
|